JP2025016451A5 - - Google Patents

Download PDF

Info

Publication number
JP2025016451A5
JP2025016451A5 JP2024168632A JP2024168632A JP2025016451A5 JP 2025016451 A5 JP2025016451 A5 JP 2025016451A5 JP 2024168632 A JP2024168632 A JP 2024168632A JP 2024168632 A JP2024168632 A JP 2024168632A JP 2025016451 A5 JP2025016451 A5 JP 2025016451A5
Authority
JP
Japan
Prior art keywords
vector
sequence
rna molecule
seq
synthetic rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024168632A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025016451A (ja
Filing date
Publication date
Priority claimed from PCT/US2017/020289 external-priority patent/WO2017151823A1/en
Application filed filed Critical
Publication of JP2025016451A publication Critical patent/JP2025016451A/ja
Publication of JP2025016451A5 publication Critical patent/JP2025016451A5/ja
Pending legal-status Critical Current

Links

JP2024168632A 2016-03-01 2024-09-27 優性網膜色素変性の治療のためのaavベクター Pending JP2025016451A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662302122P 2016-03-01 2016-03-01
US62/302,122 2016-03-01
US201662398451P 2016-09-22 2016-09-22
US62/398,451 2016-09-22
PCT/US2017/020289 WO2017151823A1 (en) 2016-03-01 2017-03-01 Aav vectors for treatment of dominant retinitis pigmentosa
JP2018545818A JP7272795B2 (ja) 2016-03-01 2017-03-01 優性網膜色素変性の治療のためのaavベクター
JP2022156496A JP7642211B2 (ja) 2016-03-01 2022-09-29 優性網膜色素変性の治療のためのaavベクター

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022156496A Division JP7642211B2 (ja) 2016-03-01 2022-09-29 優性網膜色素変性の治療のためのaavベクター

Publications (2)

Publication Number Publication Date
JP2025016451A JP2025016451A (ja) 2025-02-04
JP2025016451A5 true JP2025016451A5 (https=) 2025-05-30

Family

ID=59743213

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018545818A Active JP7272795B2 (ja) 2016-03-01 2017-03-01 優性網膜色素変性の治療のためのaavベクター
JP2022156496A Active JP7642211B2 (ja) 2016-03-01 2022-09-29 優性網膜色素変性の治療のためのaavベクター
JP2024168632A Pending JP2025016451A (ja) 2016-03-01 2024-09-27 優性網膜色素変性の治療のためのaavベクター

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2018545818A Active JP7272795B2 (ja) 2016-03-01 2017-03-01 優性網膜色素変性の治療のためのaavベクター
JP2022156496A Active JP7642211B2 (ja) 2016-03-01 2022-09-29 優性網膜色素変性の治療のためのaavベクター

Country Status (9)

Country Link
US (2) US11118185B2 (https=)
EP (2) EP3423582B1 (https=)
JP (3) JP7272795B2 (https=)
CN (2) CN115896106A (https=)
AU (2) AU2017227776C1 (https=)
CA (1) CA3014671A1 (https=)
ES (1) ES2923877T3 (https=)
IL (2) IL302455A (https=)
WO (1) WO2017151823A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115896106A (zh) 2016-03-01 2023-04-04 佛罗里达大学研究基金会有限公司 用于治疗显性视网膜色素变性的aav载体
JP7385282B2 (ja) * 2017-11-07 2023-11-22 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 環状rna分子のための方法及び組成物
BR112020023298A2 (pt) * 2018-05-15 2021-03-09 University Of Washington composições e métodos para reduzir a spliceopatia e tratamento de distúrbios de dominância de rna
CN112204145B (zh) * 2018-06-01 2024-03-26 佛罗里达大学研究基金会有限公司 用于治疗显性视网膜色素变性的组合物和方法
GB201817469D0 (en) * 2018-10-26 2018-12-12 Univ Oxford Innovation Ltd Gene therapy for retinal disease
CN111518813B (zh) * 2019-02-03 2023-04-28 武汉纽福斯生物科技有限公司 视紫红质的编码序列、其表达载体构建及其应用
EP4013414A4 (en) * 2019-08-15 2023-09-27 The Children's Hospital of Philadelphia COMBINED INTRON-DERIVED MIRNA AND TRANSGENE THERAPY FOR THE TREATMENT OF SCA1
US20230149439A1 (en) * 2020-04-21 2023-05-18 Chigenovo Co., Ltd. Rho-adrp gene editing-based methods and compositions
CN111926044B (zh) * 2020-10-12 2021-01-22 北京大学第三医院(北京大学第三临床医学院) 结合突变rho基因的核酸分子和试剂盒
WO2022165313A1 (en) 2021-02-01 2022-08-04 Regenxbio Inc. Gene therapy for neuronal ceroid lipofuscinoses
WO2025231487A1 (en) * 2024-05-03 2025-11-06 The Trustees Of The University Of Pennsylvania Photoreceptor specific promotors for use in gene therapies for treatment of retinal degeneration

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US8551970B2 (en) 1996-04-02 2013-10-08 Optigen Patents Limited Genetic suppression and replacement
US20040234999A1 (en) 1996-04-02 2004-11-25 Farrar Gwenyth Jane Genetic suppression and replacement
GB9606961D0 (en) 1996-04-02 1996-06-05 Farrar Gwyneth J Genetic strategy III
AU2003274397A1 (en) 2002-06-05 2003-12-22 University Of Florida Production of pseudotyped recombinant aav virions
AU2004233043A1 (en) 2003-04-18 2004-11-04 The Trustees Of The University Of Pennsylvania Compositions and methods for siRNA inhibition of angiopoietin 1 and 2 and their receptor Tie2
US20070009899A1 (en) * 2003-10-02 2007-01-11 Mounts William M Nucleic acid arrays for detecting gene expression in animal models of inflammatory diseases
GB0403600D0 (en) * 2004-02-18 2004-03-24 Trinity College Dublin Methods and reagents for treating disease
CN1977044A (zh) 2004-03-24 2007-06-06 肿瘤疗法科学股份有限公司 治疗胰腺癌的组合物和方法
US20080221057A1 (en) 2007-02-16 2008-09-11 Wyeth Secreted protein ccdc80 regulates adipocyte differentiation
US20120322861A1 (en) 2007-02-23 2012-12-20 Barry John Byrne Compositions and Methods for Treating Diseases
EP2140004B1 (en) * 2007-04-12 2022-01-12 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin Genetic suppression and replacement
WO2009035792A1 (en) * 2007-08-03 2009-03-19 Melba Ketchum Compositions, methods and systems for the simultaneous determination of parentage, identity, sex, genotype and/or phenotype and breed determination in animals
WO2010127209A2 (en) * 2009-04-30 2010-11-04 The Research Foundation Of State University Of New York Compositions and methods for therapy of macular degeneration
SG10201800541SA (en) * 2010-04-23 2018-03-28 Univ Florida Raav-guanylate cyclase compositions and methods for treating leber's congenital amaurosis-1 (lca1)
KR101761388B1 (ko) 2010-07-30 2017-07-25 큐어백 아게 트랜스펙션 및 면역 자극을 위한 이황화-크로스링크된 양이온 성분 및 핵산의 복합체
CN102061308B (zh) 2010-10-29 2013-05-08 北京未名凯拓作物设计中心有限公司 一种用百草枯筛选转基因植物的方法
CN102061305B (zh) 2010-12-15 2012-07-18 深圳市百恩维生物科技有限公司 一种多ShRNA高效协同沉默基因方法及载体
US20130064815A1 (en) 2011-09-12 2013-03-14 The Trustees Of Princeton University Inducing apoptosis in quiescent cells
US11180760B2 (en) * 2012-03-09 2021-11-23 The Johns Hopkins University Identification of molecular pathways and methods of use thereof for treating retinal neurodegeneration and other neurodegenerative disorders
US9163259B2 (en) * 2012-05-04 2015-10-20 Novartis Ag Viral vectors for the treatment of retinal dystrophy
US9695443B2 (en) 2012-05-25 2017-07-04 Commissariat A L'energie Atomique Et Aux Energies Alternatives Vector for the selective silencing of a gene in astrocytes
WO2014138792A1 (en) 2013-03-14 2014-09-18 Commonwealth Scientific And Industrial Research Organisation Double-stranded rna
PL3628334T3 (pl) * 2014-03-21 2023-12-18 Genzyme Corporation Terapia genowa w retinopatii barwnikowej
AU2016222546B2 (en) 2015-02-26 2020-01-23 Ionis Pharmaceuticals, Inc. Allele specific modulators of P23H rhodopsin
EP3289080B1 (en) 2015-04-30 2021-08-25 The Trustees of Columbia University in the City of New York Gene therapy for autosomal dominant diseases
WO2017137493A1 (en) 2016-02-09 2017-08-17 Fondazione Telethon Synthetic promoters and uses thereof
US20170348387A1 (en) 2016-02-29 2017-12-07 The Trustees Of The University Of Pennsylvania Aav-mediated gene therapy for nphp5 lca-ciliopathy
CN115896106A (zh) 2016-03-01 2023-04-04 佛罗里达大学研究基金会有限公司 用于治疗显性视网膜色素变性的aav载体

Similar Documents

Publication Publication Date Title
JP2025016451A5 (https=)
JP2022185052A5 (https=)
US9150863B2 (en) Compositions and methods for siRNA inhibition of angiogenesis
US7872118B2 (en) siRNA and methods of manufacture
EP2633051B1 (en) Hbv treatment
US8470792B2 (en) Compositions and methods for selective inhibition of VEGF
JP2019511216A5 (https=)
US8227444B2 (en) Compositions and methods for inhibition of VEGF
NZ543815A (en) Double-stranded nucleic acid
JP2023540429A5 (https=)
JP2021525531A5 (https=)
IL279091B1 (en) Compositions and methods for treating dominant retinitis pigmentosa
JP2024119830A5 (https=)
US10329566B2 (en) Nucleic acid molecule, expression cassette, expression vector, eukaryotic host cell, induction method of RNA interference in eukaryotic host and use of the nucleic acid molecule in therapy of diseases induced by expansion of trinucleotide CAG repeats
JP2020503014A5 (https=)
JP2019513395A5 (https=)
CA2542871A1 (en) Retroviral vectors for delivery of interfering rna
KR20130012095A (ko) TGF-β1 발현을 억제하는 shRNA
RU2018142797A (ru) Средства для лечения инфекции вируса гепатита в (hbv) и их применение
HK1234090B (en) Hbv treatment